Research groups All groups >>

Servei de Hematologia

HEMATO-IDIBAPS

Servei de Hematologia

Hospital Clínic - Institut d’Investigacions Biomèdiques August Pi i Sunyer. Barcelona

A multidisciplinary team of investigators with expertise in Haematology, Pharmacology, Biology and Biochemistry, with particular emphasis in the mechanisms involved in the physiology and pathology of haemostasisa and the vascular environment.

Our primary line of research is directed toward thrombosis, from a broad perspective that incorporates the basic mechanisms, diagnosis, prognosis, and treatment. The ultimate objective of our research is to improve our knowledge of thrombotic pathology and thereby reduce morbidity and mortality, and improve the quality of life for the at-risk population. To achieve this objective, our group:

  • Possesses experience with the study of endothelial dysfunction in diverse clinical situations associated with elevated cardiovascular risk, has recreated models of dysfunction in cell cultures and has the technology needed for the detection of cell and humoural markers in circulating blood.
  • Analyses genetic polymorphisms involved in haemostatic pathologies. Testing for haemostasis and activation markers, and procoagulant activity.
  • Contributes in-depth knowledge of the mechanisms of platelet function and the implications of biogenic amines (5HT and epinephrine) and antithrombotic agents in the development/inhibition of ischemic complications.
  • Possesses extensive experience in the application of animal models of thrombosis and of sepsis, generalized by endotoxemia, which allows for the study in vivo of the inflammatory mechanisms (knock outs, transgenic models).

The group has more than 20 years of experience in its area of expertise and collaborates with other research groups in Cardiology, Nephrology, Psychiatry, Autoimmune Diseases, and Endocrinology, which reinforce its own research capacity and the transfer of research results. It also has a high capacity for intra- and extramural training, and for the dissemination of results (publications and web: www.platelet-research.org).

Latest publications

  • Lopez-Vilchez I, Diaz-Ricart M, Galán AM, Roqué M, Caballo C, Molina P, White JG, Escolar G Internalization of Tissue Factor-Rich Microvesicles by Platelets Occurs Independently of GPIIb-IIIa, and Involves CD36 Receptor, Serotonin Transporter and Cytoskeletal Assembly. J. Cell. Biochem. 2016; 117: 448-57

    View abstract

  • Fernández-Ruiz R, Pino M, Hurtado B, García de Frutos P, Caballo C, Escolar G, Gomis R, Diaz-Ricart M Role of sodium tungstate as a potential antiplatelet agent. Drug Des Devel Ther 2015; 9: 2777-86

    View abstract

  • Barón Esquivias G, Escolar Albaladejo G, Zamorano JL, Betegón Nicolás L, Canal Fontcuberta C, de Salas-Cansado M, Rubio-Rodríguez D, Rubio-Terrés C Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. Rev Esp Cardiol (Engl Ed) 2015; 68: 680-90

    View abstract

  • Arellano-Rodrigo E, Lopez-Vilchez I, Galán AM, Molina P, Reverter JC, Carne X, Villalta J, Tàssies D, Lozano M, Diaz-Ricart M, Escolar G Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. Transfus Med Rev 2015; 29: 242-9

    View abstract

  • Martin-Rodriguez S, Caballo C, Gutiérrez G, Vera M, Cruzado JM, Cases A, Escolar G, Diaz-Ricart M TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia. Eur. J. Clin. Invest. 2015; 45: 160-9

    View abstract

  • Cid J, Lozano M, Ziman A, West KA, O'Brien KL, Murphy MF, Wendel S, Vázquez A, Ortín X, Hervig TA, Delaney M, Flegel WA, Yazer MH Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. Br. J. Haematol. 2015; 168: 598-603

    View abstract

  • Cid J, Magnano L, Acosta M, Alba C, Esteve J, Lozano M Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness. Platelets 2015; 26: 190-4

    View abstract

  • Cuadrado-Godia E, Regueiro A, Núñez J, Díaz-Ricard M, Novella S, Oliveras A, Valverde MA, Marrugat J, Ois A, Giralt-Steinhauer E, Sanchis J, Escolar G, Hermenegildo C, Heras M, Roquer J Endothelial Progenitor Cells Predict Cardiovascular Events after Atherothrombotic Stroke and Acute Myocardial Infarction. A PROCELL Substudy. PLoS ONE 2015; 10: e0132415

    View abstract

  • Escolar G, Carne X, Arellano-Rodrigo E Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opin Drug Metab Toxicol 2015; 11: 1665-77

    View abstract

  • Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I, Molina P, Sanchis J, Reverter JC, Carne X, Cid J, Villalta J, Tàssies D, Galán AM, Diaz-Ricart M Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood. Circ. J. 2015; 79: 331-8

    View abstract

All publications

An initiative of

Ministerio de Economía y Competitividad Fondo Europeo de Desarrollo Regional IMIM - Parc de Salut Mar